**Summary**

**Enrolled:** 7 patients

|  |  |
| --- | --- |
| Variable | N (%) |
| Sex |  |
|  | Females | 3 (42.9) |
|  | Males | 4 (57.1) |
| Mean age at enrolment | 50.4 years |
|  | 30-39 years | 1 (14.3) |
|  | 40-49 years | 2 (28.6) |
|  | 50-59 years | 3 (42.8) |
|  | ≥60 years | 1 (14.3) |
| History of confirmed dengue infection | 7 (100.0) |
| Mean time since dengue infection | 9.7 years |
|  | <10 years | 4 (57.1) |
|  | ≥10 years | 2 (28.6) |
|  | Unknown | 1 (14.3) |
| Place of dengue infection |  |
|  | Asia (Bangladesh, Indonesia, Malaysia, Thailand) | 4 (57.1) |
|  | Oceania (PNG) | 1 (14.3) |
|  | Unsure (Mexico/PNG ; Mexico/Africa) | 2 (28.6) |
| Number of days sick (off work) due to dengue |  |
|  | <7 days | 1 (14.3) |
|  | 7-13 days | 1 (14.3) |
|  | 14-20 days | 2 (28.6) |
|  | ≥21 days | 2 (28.6)\* |
|  | Unknown | 1 (14.3) |
| Region where patient plans to spend >3 months in the next 3 years § |  |
|  | Asia (Bangladesh, Malaysia, Singapore, Thailand, Philippines) | 6 (54.5) |
|  | Africa (Kenya) | 2 (18.2)  |
|  | Oceania (PNG) | 3 (27.3) |
| Reason for travel to tropical areas |  |
|  | Work | 4 (57.1) |
|  | Lives there | 1 (14.3) |
|  | Tourism | 2 (28.6) |
| Comorbidities |  |
|  | Diabetes | 1 (14.3)  |
|  | Hypothyroidism | 1 (14.3)  |
|  | None | 5 (71.4) |
| \*Both patients spent 4 days admitted in hospital§4 patients plan to spend time in more than 1 region |

**Follow-up:** 5 patients have completed 3 doses, 2 patient has received 2 doses (20 encounters recorded)

|  |  |
| --- | --- |
| Variable | N (%) |
| Patient reported adverse events following immunisation |  |
|  | Yes\* | 2 (28.6) |
|  | No | 5 (71.4) |
| \*Did not impact normal daily impact |

Patient 1

* First dose: Headache, redness and itchiness around injection site. Required aspirin for headache.
* Second dose: No AEFI.
* Third dose: Swollen gland in neck.

Patient 2

* First dose: No AEFI.
* Second dose: Sore arm and metallic taste.
* Third dose: Not yet administered.